Notice: Official Public Record
Is US Compounding Inc Safe? FDA Warning Letter Review (2017)
Compiled by the Supplement Safety Data Team | Sourced from Official FDA Records on October 10, 2017
MODERATE SEVERITY
Dallas District Office 2017
Disclaimer: This report is an analysis of a public FDA warning
letter. It is not medical advice. If you have consumed these products and feel
unwell, contact a healthcare professional immediately.
Executive Summary
The FDA issued a warning letter to US Compounding Inc on October 10, 2017 citing regulatory violations. The letter was issued by Dallas District Office.
Regulatory Violations
Detailed Analysis
False Claims and Regulatory Violations
The FDA identified regulatory violations in US Compounding Inc's operations or product claims.
Potential Health Risks
Office of Pharmaceutical Quality Operations, Division II4040 N. Central Expressway, Suite 300Dallas, Texas 75204
Regulatory Context
This warning letter is part of the FDA's enforcement of federal regulations.
Key Entities Identified
US Compounding Inc FDA Warning Letter
Frequently Asked Questions
- What did the FDA find wrong with US Compounding Inc?
- The FDA issued a warning letter citing regulatory violations related to their products or manufacturing practices.
- Are US Compounding Inc products safe to use?
- Based on the FDA's findings, consumers should exercise caution. The company was found to have regulatory issues that may affect product safety.
- What should I do if I've used US Compounding Inc products?
- If you have used products from US Compounding Inc and experience any adverse effects, contact your healthcare provider immediately. You can also report adverse events to the FDA's MedWatch program.
Source Document
This report is based on an official FDA warning letter. The original document is a public record.
View Original FDA Warning Letter Medical Disclaimer: This report is an analysis of public FDA
warning letters. It is not medical advice. If you have consumed these products
and feel unwell, contact a healthcare professional immediately. You can report
adverse events to the
FDA MedWatch program.